市场调查报告书

人体微生物的全球市场

Human Microbiome

出版商 Global Industry Analysts, Inc. 商品编码 957048
出版日期 内容资讯 英文 247 Pages
商品交期: 最快1-2个工作天内
价格
人体微生物的全球市场 Human Microbiome
出版日期: 2020年09月01日内容资讯: 英文 247 Pages
简介

全球人体微生物的市场规模在2020年~2027年的分析期间中预计将以13.8%的年复合成长率增长,从2020年的3亿9,100万美元到2027年达到9亿6,450万美元。市场区隔之一的急性腹泻部门在分析期间结束前预测将以14.9%的年率增长,达到5亿2,700万美元的规模。

本报告提供全球人体微生物市场的相关调查,提供市场占有率,趋势和预测,成长要素,各地区的市场分析,竞争情形,主要企业的简介等资讯。

调查对象企业范例

  • DowDuPont, Inc.
  • Enterome SA
  • Merck & Co., Inc.
  • Metabiomics Corporation
  • Microbiome Therapeutics, LLC.
  • Osel, Inc.
  • Second Genome
  • Vedanta Biosciences, Inc.
  • ViThera Pharmaceuticals, Inc.
  • Yakult Honsha Co., Ltd.

目录

I. 简介,调查手法,调查范围

II. 摘要整理

  • 市场概要
    • Covid-19的影响和即将到来的全球景气衰退
    • 竞争的市场占有率
    • 竞争的市场占有率方案
  • 主要企业
  • 趋势与成长要素
  • 全球市场预测

III. 市场分析

  • 各地区市场分析
  • 美国
  • 加拿大
  • 日本
  • 中国
  • 欧洲
  • 法国
  • 德国
  • 义大利
  • 英国
  • 其他欧洲
  • 亚太地区
  • 其他地区

IV. 竞争

  • 企业简介:44公司
目录
Product Code: MCP12453

Global Human Microbiome Market to Reach US$964.5 Million by the Year 2027

Amid the COVID-19 crisis, the global market for Human Microbiome estimated at US$391 Million in the year 2020, is projected to reach a revised size of US$964.5 Million by 2027, growing at a CAGR of 13.8% over the analysis period 2020-2027.Acute Diarrhea, one of the segments analyzed in the report, is projected to grow at a 14.9% CAGR to reach US$527 Million by the end of the analysis period.After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Obesity segment is readjusted to a revised 12.6% CAGR for the next 7-year period. This segment currently accounts for a 4.7% share of the global Human Microbiome market.

The U.S. Accounts for Over 29.6% of Global Market Size in 2020, While China is Forecast to Grow at a 13.2% CAGR for the Period of 2020-2027

The Human Microbiome market in the U.S. is estimated at US$115.6 Million in the year 2020. The country currently accounts for a 29.56% share in the global market. China, the world second largest economy, is forecast to reach an estimated market size of US$167.2 Million in the year 2027 trailing a CAGR of 13.2% through 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 12.2% and 11.7% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 10% CAGR while Rest of European market (as defined in the study) will reach US$167.2 Million by the year 2027.

Diabetes Segment Corners a 3.8% Share in 2020

In the global Diabetes segment, USA, Canada, Japan, China and Europe will drive the 13.9% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$12 Million in the year 2020 will reach a projected size of US$29.8 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$114.2 Million by the year 2027.We bring years of research experience to this 8th edition of our report. The 247-page report presents concise insights into how the pandemic has impacted production and the buy side for 2020 and 2021. A short-term phased recovery by key geography is also addressed.

Competitors identified in this market include, among others,

  • DowDuPont, Inc.
  • Enterome SA
  • Merck & Co., Inc.
  • Metabiomics Corporation
  • Microbiome Therapeutics, LLC.
  • Osel, Inc.
  • Second Genome
  • Vedanta Biosciences, Inc.
  • ViThera Pharmaceuticals, Inc.
  • Yakult Honsha Co., Ltd.

TABLE OF CONTENTS

I. INTRODUCTION, METHODOLOGY & REPORT SCOPE

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Impact of Covid-19 and a Looming Global Recession
    • Global Competitor Market Shares
    • Human Microbiome Competitor Market Share Scenario Worldwide (in %): 2018E
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Current & Future Analysis for Human Microbiome by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through
    • TABLE 2: World Historic Review for Human Microbiome by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through
    • TABLE 3: World 15-Year Perspective for Human Microbiome by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2012, 2018 & 2027
    • TABLE 4: World Current & Future Analysis for Acute Diarrhea by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through
    • TABLE 5: World Historic Review for Acute Diarrhea by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through
    • TABLE 6: World 15-Year Perspective for Acute Diarrhea by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2018 & 2027
    • TABLE 7: World Current & Future Analysis for Obesity by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through
    • TABLE 8: World Historic Review for Obesity by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through
    • TABLE 9: World 15-Year Perspective for Obesity by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2018 & 2027
    • TABLE 10: World Current & Future Analysis for Diabetes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through
    • TABLE 11: World Historic Review for Diabetes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through
    • TABLE 12: World 15-Year Perspective for Diabetes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2018 & 2027
    • TABLE 13: World Current & Future Analysis for Autoimmune Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through
    • TABLE 14: World Historic Review for Autoimmune Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through
    • TABLE 15: World 15-Year Perspective for Autoimmune Disorders by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2018 & 2027
    • TABLE 16: World Current & Future Analysis for Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through
    • TABLE 17: World Historic Review for Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through
    • TABLE 18: World 15-Year Perspective for Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2018 & 2027
    • TABLE 19: World Current & Future Analysis for Mental Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through
    • TABLE 20: World Historic Review for Mental Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through
    • TABLE 21: World 15-Year Perspective for Mental Disorders by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2018 & 2027
    • TABLE 22: World Current & Future Analysis for Other Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through
    • TABLE 23: World Historic Review for Other Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through
    • TABLE 24: World 15-Year Perspective for Other Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2018 & 2027
    • TABLE 25: World Current & Future Analysis for Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through
    • TABLE 26: World Historic Review for Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through
    • TABLE 27: World 15-Year Perspective for Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2018 & 2027
    • TABLE 28: World Current & Future Analysis for Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through
    • TABLE 29: World Historic Review for Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through
    • TABLE 30: World 15-Year Perspective for Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2018 & 2027
    • TABLE 31: World Current & Future Analysis for Probiotics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through
    • TABLE 32: World Historic Review for Probiotics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through
    • TABLE 33: World 15-Year Perspective for Probiotics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2018 & 2027
    • TABLE 34: World Current & Future Analysis for Prebiotics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through
    • TABLE 35: World Historic Review for Prebiotics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through
    • TABLE 36: World 15-Year Perspective for Prebiotics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2018 & 2027
    • TABLE 37: World Current & Future Analysis for Foods by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through
    • TABLE 38: World Historic Review for Foods by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through
    • TABLE 39: World 15-Year Perspective for Foods by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2018 & 2027
    • TABLE 40: World Current & Future Analysis for Medical Foods by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through
    • TABLE 41: World Historic Review for Medical Foods by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through
    • TABLE 42: World 15-Year Perspective for Medical Foods by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2018 & 2027
    • TABLE 43: World Current & Future Analysis for Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through
    • TABLE 44: World Historic Review for Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through
    • TABLE 45: World 15-Year Perspective for Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2018 & 2027
    • TABLE 46: World Current & Future Analysis for Other Product Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through
    • TABLE 47: World Historic Review for Other Product Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through
    • TABLE 48: World 15-Year Perspective for Other Product Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2018 & 2027

III. MARKET ANALYSIS

  • GEOGRAPHIC MARKET ANALYSIS
  • UNITED STATES
    • Market Facts & Figures
    • US Human Microbiome Market Share (in %) by Company: 2018 &
    • Market Analytics
    • TABLE 49: USA Current & Future Analysis for Human Microbiome by Disease Indication - Acute Diarrhea, Obesity, Diabetes, Autoimmune Disorders, Cancer, Mental Disorders and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through
    • TABLE 50: USA Historic Review for Human Microbiome by Disease Indication - Acute Diarrhea, Obesity, Diabetes, Autoimmune Disorders, Cancer, Mental Disorders and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through
    • TABLE 51: USA 15-Year Perspective for Human Microbiome by Disease Indication - Percentage Breakdown of Value Sales for Acute Diarrhea, Obesity, Diabetes, Autoimmune Disorders, Cancer, Mental Disorders and Other Diseases for the Years 2012, 2018 & 2027
    • TABLE 52: USA Current & Future Analysis for Human Microbiome by Application - Therapeutics and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through
    • TABLE 53: USA Historic Review for Human Microbiome by Application - Therapeutics and Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through
    • TABLE 54: USA 15-Year Perspective for Human Microbiome by Application - Percentage Breakdown of Value Sales for Therapeutics and Diagnostics for the Years 2012, 2018 & 2027
    • TABLE 55: USA Current & Future Analysis for Human Microbiome by Product Type - Probiotics, Prebiotics, Foods, Medical Foods, Drugs and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through
    • TABLE 56: USA Historic Review for Human Microbiome by Product Type - Probiotics, Prebiotics, Foods, Medical Foods, Drugs and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through
    • TABLE 57: USA 15-Year Perspective for Human Microbiome by Product Type - Percentage Breakdown of Value Sales for Probiotics, Prebiotics, Foods, Medical Foods, Drugs and Other Product Types for the Years 2012, 2018 & 2027
  • CANADA
    • TABLE 58: Canada Current & Future Analysis for Human Microbiome by Disease Indication - Acute Diarrhea, Obesity, Diabetes, Autoimmune Disorders, Cancer, Mental Disorders and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through
    • TABLE 59: Canada Historic Review for Human Microbiome by Disease Indication - Acute Diarrhea, Obesity, Diabetes, Autoimmune Disorders, Cancer, Mental Disorders and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through
    • TABLE 60: Canada 15-Year Perspective for Human Microbiome by Disease Indication - Percentage Breakdown of Value Sales for Acute Diarrhea, Obesity, Diabetes, Autoimmune Disorders, Cancer, Mental Disorders and Other Diseases for the Years 2012, 2018 & 2027
    • TABLE 61: Canada Current & Future Analysis for Human Microbiome by Application - Therapeutics and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through
    • TABLE 62: Canada Historic Review for Human Microbiome by Application - Therapeutics and Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through
    • TABLE 63: Canada 15-Year Perspective for Human Microbiome by Application - Percentage Breakdown of Value Sales for Therapeutics and Diagnostics for the Years 2012, 2018 & 2027
    • TABLE 64: Canada Current & Future Analysis for Human Microbiome by Product Type - Probiotics, Prebiotics, Foods, Medical Foods, Drugs and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through
    • TABLE 65: Canada Historic Review for Human Microbiome by Product Type - Probiotics, Prebiotics, Foods, Medical Foods, Drugs and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through
    • TABLE 66: Canada 15-Year Perspective for Human Microbiome by Product Type - Percentage Breakdown of Value Sales for Probiotics, Prebiotics, Foods, Medical Foods, Drugs and Other Product Types for the Years 2012, 2018 & 2027
  • JAPAN
    • TABLE 67: Japan Current & Future Analysis for Human Microbiome by Disease Indication - Acute Diarrhea, Obesity, Diabetes, Autoimmune Disorders, Cancer, Mental Disorders and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through
    • TABLE 68: Japan Historic Review for Human Microbiome by Disease Indication - Acute Diarrhea, Obesity, Diabetes, Autoimmune Disorders, Cancer, Mental Disorders and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through
    • TABLE 69: Japan 15-Year Perspective for Human Microbiome by Disease Indication - Percentage Breakdown of Value Sales for Acute Diarrhea, Obesity, Diabetes, Autoimmune Disorders, Cancer, Mental Disorders and Other Diseases for the Years 2012, 2018 & 2027
    • TABLE 70: Japan Current & Future Analysis for Human Microbiome by Application - Therapeutics and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through
    • TABLE 71: Japan Historic Review for Human Microbiome by Application - Therapeutics and Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through
    • TABLE 72: Japan 15-Year Perspective for Human Microbiome by Application - Percentage Breakdown of Value Sales for Therapeutics and Diagnostics for the Years 2012, 2018 & 2027
    • TABLE 73: Japan Current & Future Analysis for Human Microbiome by Product Type - Probiotics, Prebiotics, Foods, Medical Foods, Drugs and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through
    • TABLE 74: Japan Historic Review for Human Microbiome by Product Type - Probiotics, Prebiotics, Foods, Medical Foods, Drugs and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through
    • TABLE 75: Japan 15-Year Perspective for Human Microbiome by Product Type - Percentage Breakdown of Value Sales for Probiotics, Prebiotics, Foods, Medical Foods, Drugs and Other Product Types for the Years 2012, 2018 & 2027
  • CHINA
    • TABLE 76: China Current & Future Analysis for Human Microbiome by Disease Indication - Acute Diarrhea, Obesity, Diabetes, Autoimmune Disorders, Cancer, Mental Disorders and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through
    • TABLE 77: China Historic Review for Human Microbiome by Disease Indication - Acute Diarrhea, Obesity, Diabetes, Autoimmune Disorders, Cancer, Mental Disorders and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through
    • TABLE 78: China 15-Year Perspective for Human Microbiome by Disease Indication - Percentage Breakdown of Value Sales for Acute Diarrhea, Obesity, Diabetes, Autoimmune Disorders, Cancer, Mental Disorders and Other Diseases for the Years 2012, 2018 & 2027
    • TABLE 79: China Current & Future Analysis for Human Microbiome by Application - Therapeutics and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through
    • TABLE 80: China Historic Review for Human Microbiome by Application - Therapeutics and Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through
    • TABLE 81: China 15-Year Perspective for Human Microbiome by Application - Percentage Breakdown of Value Sales for Therapeutics and Diagnostics for the Years 2012, 2018 & 2027
    • TABLE 82: China Current & Future Analysis for Human Microbiome by Product Type - Probiotics, Prebiotics, Foods, Medical Foods, Drugs and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through
    • TABLE 83: China Historic Review for Human Microbiome by Product Type - Probiotics, Prebiotics, Foods, Medical Foods, Drugs and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through
    • TABLE 84: China 15-Year Perspective for Human Microbiome by Product Type - Percentage Breakdown of Value Sales for Probiotics, Prebiotics, Foods, Medical Foods, Drugs and Other Product Types for the Years 2012, 2018 & 2027
  • EUROPE
    • Market Facts & Figures
    • European Human Microbiome Market: Competitor Market Share Scenario (in %) for 2018 &
    • Market Analytics
    • TABLE 85: Europe Current & Future Analysis for Human Microbiome by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2018 through
    • TABLE 86: Europe Historic Review for Human Microbiome by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through
    • TABLE 87: Europe 15-Year Perspective for Human Microbiome by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2012, 2018 & 2027
    • TABLE 88: Europe Current & Future Analysis for Human Microbiome by Disease Indication - Acute Diarrhea, Obesity, Diabetes, Autoimmune Disorders, Cancer, Mental Disorders and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through
    • TABLE 89: Europe Historic Review for Human Microbiome by Disease Indication - Acute Diarrhea, Obesity, Diabetes, Autoimmune Disorders, Cancer, Mental Disorders and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through
    • TABLE 90: Europe 15-Year Perspective for Human Microbiome by Disease Indication - Percentage Breakdown of Value Sales for Acute Diarrhea, Obesity, Diabetes, Autoimmune Disorders, Cancer, Mental Disorders and Other Diseases for the Years 2012, 2018 & 2027
    • TABLE 91: Europe Current & Future Analysis for Human Microbiome by Application - Therapeutics and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through
    • TABLE 92: Europe Historic Review for Human Microbiome by Application - Therapeutics and Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through
    • TABLE 93: Europe 15-Year Perspective for Human Microbiome by Application - Percentage Breakdown of Value Sales for Therapeutics and Diagnostics for the Years 2012, 2018 & 2027
    • TABLE 94: Europe Current & Future Analysis for Human Microbiome by Product Type - Probiotics, Prebiotics, Foods, Medical Foods, Drugs and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through
    • TABLE 95: Europe Historic Review for Human Microbiome by Product Type - Probiotics, Prebiotics, Foods, Medical Foods, Drugs and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through
    • TABLE 96: Europe 15-Year Perspective for Human Microbiome by Product Type - Percentage Breakdown of Value Sales for Probiotics, Prebiotics, Foods, Medical Foods, Drugs and Other Product Types for the Years 2012, 2018 & 2027
  • FRANCE
    • TABLE 97: France Current & Future Analysis for Human Microbiome by Disease Indication - Acute Diarrhea, Obesity, Diabetes, Autoimmune Disorders, Cancer, Mental Disorders and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through
    • TABLE 98: France Historic Review for Human Microbiome by Disease Indication - Acute Diarrhea, Obesity, Diabetes, Autoimmune Disorders, Cancer, Mental Disorders and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through
    • TABLE 99: France 15-Year Perspective for Human Microbiome by Disease Indication - Percentage Breakdown of Value Sales for Acute Diarrhea, Obesity, Diabetes, Autoimmune Disorders, Cancer, Mental Disorders and Other Diseases for the Years 2012, 2018 & 2027
    • TABLE 100: France Current & Future Analysis for Human Microbiome by Application - Therapeutics and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through
    • TABLE 101: France Historic Review for Human Microbiome by Application - Therapeutics and Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through
    • TABLE 102: France 15-Year Perspective for Human Microbiome by Application - Percentage Breakdown of Value Sales for Therapeutics and Diagnostics for the Years 2012, 2018 & 2027
    • TABLE 103: France Current & Future Analysis for Human Microbiome by Product Type - Probiotics, Prebiotics, Foods, Medical Foods, Drugs and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through
    • TABLE 104: France Historic Review for Human Microbiome by Product Type - Probiotics, Prebiotics, Foods, Medical Foods, Drugs and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through
    • TABLE 105: France 15-Year Perspective for Human Microbiome by Product Type - Percentage Breakdown of Value Sales for Probiotics, Prebiotics, Foods, Medical Foods, Drugs and Other Product Types for the Years 2012, 2018 & 2027
  • GERMANY
    • TABLE 106: Germany Current & Future Analysis for Human Microbiome by Disease Indication - Acute Diarrhea, Obesity, Diabetes, Autoimmune Disorders, Cancer, Mental Disorders and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through
    • TABLE 107: Germany Historic Review for Human Microbiome by Disease Indication - Acute Diarrhea, Obesity, Diabetes, Autoimmune Disorders, Cancer, Mental Disorders and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through
    • TABLE 108: Germany 15-Year Perspective for Human Microbiome by Disease Indication - Percentage Breakdown of Value Sales for Acute Diarrhea, Obesity, Diabetes, Autoimmune Disorders, Cancer, Mental Disorders and Other Diseases for the Years 2012, 2018 & 2027
    • TABLE 109: Germany Current & Future Analysis for Human Microbiome by Application - Therapeutics and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through
    • TABLE 110: Germany Historic Review for Human Microbiome by Application - Therapeutics and Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through
    • TABLE 111: Germany 15-Year Perspective for Human Microbiome by Application - Percentage Breakdown of Value Sales for Therapeutics and Diagnostics for the Years 2012, 2018 & 2027
    • TABLE 112: Germany Current & Future Analysis for Human Microbiome by Product Type - Probiotics, Prebiotics, Foods, Medical Foods, Drugs and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through
    • TABLE 113: Germany Historic Review for Human Microbiome by Product Type - Probiotics, Prebiotics, Foods, Medical Foods, Drugs and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through
    • TABLE 114: Germany 15-Year Perspective for Human Microbiome by Product Type - Percentage Breakdown of Value Sales for Probiotics, Prebiotics, Foods, Medical Foods, Drugs and Other Product Types for the Years 2012, 2018 & 2027
  • ITALY
    • TABLE 115: Italy Current & Future Analysis for Human Microbiome by Disease Indication - Acute Diarrhea, Obesity, Diabetes, Autoimmune Disorders, Cancer, Mental Disorders and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through
    • TABLE 116: Italy Historic Review for Human Microbiome by Disease Indication - Acute Diarrhea, Obesity, Diabetes, Autoimmune Disorders, Cancer, Mental Disorders and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through
    • TABLE 117: Italy 15-Year Perspective for Human Microbiome by Disease Indication - Percentage Breakdown of Value Sales for Acute Diarrhea, Obesity, Diabetes, Autoimmune Disorders, Cancer, Mental Disorders and Other Diseases for the Years 2012, 2018 & 2027
    • TABLE 118: Italy Current & Future Analysis for Human Microbiome by Application - Therapeutics and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through
    • TABLE 119: Italy Historic Review for Human Microbiome by Application - Therapeutics and Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through
    • TABLE 120: Italy 15-Year Perspective for Human Microbiome by Application - Percentage Breakdown of Value Sales for Therapeutics and Diagnostics for the Years 2012, 2018 & 2027
    • TABLE 121: Italy Current & Future Analysis for Human Microbiome by Product Type - Probiotics, Prebiotics, Foods, Medical Foods, Drugs and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through
    • TABLE 122: Italy Historic Review for Human Microbiome by Product Type - Probiotics, Prebiotics, Foods, Medical Foods, Drugs and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through
    • TABLE 123: Italy 15-Year Perspective for Human Microbiome by Product Type - Percentage Breakdown of Value Sales for Probiotics, Prebiotics, Foods, Medical Foods, Drugs and Other Product Types for the Years 2012, 2018 & 2027
  • UNITED KINGDOM
    • TABLE 124: UK Current & Future Analysis for Human Microbiome by Disease Indication - Acute Diarrhea, Obesity, Diabetes, Autoimmune Disorders, Cancer, Mental Disorders and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through
    • TABLE 125: UK Historic Review for Human Microbiome by Disease Indication - Acute Diarrhea, Obesity, Diabetes, Autoimmune Disorders, Cancer, Mental Disorders and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through
    • TABLE 126: UK 15-Year Perspective for Human Microbiome by Disease Indication - Percentage Breakdown of Value Sales for Acute Diarrhea, Obesity, Diabetes, Autoimmune Disorders, Cancer, Mental Disorders and Other Diseases for the Years 2012, 2018 & 2027
    • TABLE 127: UK Current & Future Analysis for Human Microbiome by Application - Therapeutics and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through
    • TABLE 128: UK Historic Review for Human Microbiome by Application - Therapeutics and Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through
    • TABLE 129: UK 15-Year Perspective for Human Microbiome by Application - Percentage Breakdown of Value Sales for Therapeutics and Diagnostics for the Years 2012, 2018 & 2027
    • TABLE 130: UK Current & Future Analysis for Human Microbiome by Product Type - Probiotics, Prebiotics, Foods, Medical Foods, Drugs and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through
    • TABLE 131: UK Historic Review for Human Microbiome by Product Type - Probiotics, Prebiotics, Foods, Medical Foods, Drugs and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through
    • TABLE 132: UK 15-Year Perspective for Human Microbiome by Product Type - Percentage Breakdown of Value Sales for Probiotics, Prebiotics, Foods, Medical Foods, Drugs and Other Product Types for the Years 2012, 2018 & 2027
  • REST OF EUROPE
    • TABLE 133: Rest of Europe Current & Future Analysis for Human Microbiome by Disease Indication - Acute Diarrhea, Obesity, Diabetes, Autoimmune Disorders, Cancer, Mental Disorders and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through
    • TABLE 134: Rest of Europe Historic Review for Human Microbiome by Disease Indication - Acute Diarrhea, Obesity, Diabetes, Autoimmune Disorders, Cancer, Mental Disorders and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through
    • TABLE 135: Rest of Europe 15-Year Perspective for Human Microbiome by Disease Indication - Percentage Breakdown of Value Sales for Acute Diarrhea, Obesity, Diabetes, Autoimmune Disorders, Cancer, Mental Disorders and Other Diseases for the Years 2012, 2018 & 2027
    • TABLE 136: Rest of Europe Current & Future Analysis for Human Microbiome by Application - Therapeutics and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through
    • TABLE 137: Rest of Europe Historic Review for Human Microbiome by Application - Therapeutics and Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through
    • TABLE 138: Rest of Europe 15-Year Perspective for Human Microbiome by Application - Percentage Breakdown of Value Sales for Therapeutics and Diagnostics for the Years 2012, 2018 & 2027
    • TABLE 139: Rest of Europe Current & Future Analysis for Human Microbiome by Product Type - Probiotics, Prebiotics, Foods, Medical Foods, Drugs and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through
    • TABLE 140: Rest of Europe Historic Review for Human Microbiome by Product Type - Probiotics, Prebiotics, Foods, Medical Foods, Drugs and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through
    • TABLE 141: Rest of Europe 15-Year Perspective for Human Microbiome by Product Type - Percentage Breakdown of Value Sales for Probiotics, Prebiotics, Foods, Medical Foods, Drugs and Other Product Types for the Years 2012, 2018 & 2027
  • ASIA-PACIFIC
    • TABLE 142: Asia-Pacific Current & Future Analysis for Human Microbiome by Disease Indication - Acute Diarrhea, Obesity, Diabetes, Autoimmune Disorders, Cancer, Mental Disorders and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through
    • TABLE 143: Asia-Pacific Historic Review for Human Microbiome by Disease Indication - Acute Diarrhea, Obesity, Diabetes, Autoimmune Disorders, Cancer, Mental Disorders and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through
    • TABLE 144: Asia-Pacific 15-Year Perspective for Human Microbiome by Disease Indication - Percentage Breakdown of Value Sales for Acute Diarrhea, Obesity, Diabetes, Autoimmune Disorders, Cancer, Mental Disorders and Other Diseases for the Years 2012, 2018 & 2027
    • TABLE 145: Asia-Pacific Current & Future Analysis for Human Microbiome by Application - Therapeutics and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through
    • TABLE 146: Asia-Pacific Historic Review for Human Microbiome by Application - Therapeutics and Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through
    • TABLE 147: Asia-Pacific 15-Year Perspective for Human Microbiome by Application - Percentage Breakdown of Value Sales for Therapeutics and Diagnostics for the Years 2012, 2018 & 2027
    • TABLE 148: Asia-Pacific Current & Future Analysis for Human Microbiome by Product Type - Probiotics, Prebiotics, Foods, Medical Foods, Drugs and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through
    • TABLE 149: Asia-Pacific Historic Review for Human Microbiome by Product Type - Probiotics, Prebiotics, Foods, Medical Foods, Drugs and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through
    • TABLE 150: Asia-Pacific 15-Year Perspective for Human Microbiome by Product Type - Percentage Breakdown of Value Sales for Probiotics, Prebiotics, Foods, Medical Foods, Drugs and Other Product Types for the Years 2012, 2018 & 2027
  • REST OF WORLD
    • TABLE 151: Rest of World Current & Future Analysis for Human Microbiome by Disease Indication - Acute Diarrhea, Obesity, Diabetes, Autoimmune Disorders, Cancer, Mental Disorders and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through
    • TABLE 152: Rest of World Historic Review for Human Microbiome by Disease Indication - Acute Diarrhea, Obesity, Diabetes, Autoimmune Disorders, Cancer, Mental Disorders and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through
    • TABLE 153: Rest of World 15-Year Perspective for Human Microbiome by Disease Indication - Percentage Breakdown of Value Sales for Acute Diarrhea, Obesity, Diabetes, Autoimmune Disorders, Cancer, Mental Disorders and Other Diseases for the Years 2012, 2018 & 2027
    • TABLE 154: Rest of World Current & Future Analysis for Human Microbiome by Application - Therapeutics and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through
    • TABLE 155: Rest of World Historic Review for Human Microbiome by Application - Therapeutics and Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through
    • TABLE 156: Rest of World 15-Year Perspective for Human Microbiome by Application - Percentage Breakdown of Value Sales for Therapeutics and Diagnostics for the Years 2012, 2018 & 2027
    • TABLE 157: Rest of World Current & Future Analysis for Human Microbiome by Product Type - Probiotics, Prebiotics, Foods, Medical Foods, Drugs and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2018 through
    • TABLE 158: Rest of World Historic Review for Human Microbiome by Product Type - Probiotics, Prebiotics, Foods, Medical Foods, Drugs and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through
    • TABLE 159: Rest of World 15-Year Perspective for Human Microbiome by Product Type - Percentage Breakdown of Value Sales for Probiotics, Prebiotics, Foods, Medical Foods, Drugs and Other Product Types for the Years 2012, 2018 & 2027

IV. COMPETITION

  • Total Companies Profiled: 44